Rating Watching: Aclaris Therapeutics (ACRS) Is Now Covered By One More Research Firm

November 29, 2016 - By Hazel Jackson

Rating Watching: Aclaris Therapeutics (ACRS) Is Now Covered By One More Research Firm

Why Leerink Partners Gives Aclaris Therapeutics (ACRS) $54.0 Price Target

Leerink Partners revealed to clients in a report that it has started coverage on Aclaris Therapeutics (ACRS) stock, with a “Outperform” rating and a $54.0 target.

Aclaris Therapeutics Inc (NASDAQ:ACRS) Ratings Coverage

Out of 3 analysts covering Aclaris Therap… (ACRS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $31 is the highest target while $23 is the lowest. The $30 average target is 2.25% above today’s ($29.34) stock price. Aclaris Therap… has been the topic of 4 analyst reports since March 16, 2016 according to StockzIntelligence Inc. As per Wednesday, March 16, the company rating was maintained by Citigroup. Jefferies maintained it with “Buy” rating and $23 target price in Friday, August 12 report. The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) earned “Buy” rating by Jefferies on Monday, September 19. The rating was initiated by JMP Securities on Friday, September 30 with “Mkt Outperform”.

About 103,085 shares traded hands. Aclaris Therapeutics Inc (ACRS) has risen 28.74% since April 26, 2016 and is uptrending. It has outperformed by 23.48% the S&P500.

Analysts await Aclaris Therapeutics Inc (NASDAQ:ACRS) to report earnings on March, 22. They expect $-0.67 EPS, down 139.29% or $0.39 from last year’s $-0.28 per share. After $-0.50 actual EPS reported by Aclaris Therapeutics Inc for the previous quarter, Wall Street now forecasts 34.00% negative EPS growth.

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company. The company has a market cap of $772.21 million. The Firm is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. It currently has negative earnings. The Company’s lead drug candidate, A-101 Topical Solution, is a high-concentration hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis , a non-malignant skin tumor.

According to Zacks Investment Research, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania.”

ACRS Company Profile

Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a clinical-stage specialty pharmaceutical company. The Firm is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications.

More news for Aclaris Therapeutics Inc (NASDAQ:ACRS) were recently published by: Fool.com, which released: “Why Aclaris Therapeutics, Inc. Stock Is Down Today” on November 17, 2016. Investorplace.com‘s article titled: “3 Stocks to Watch on Wednesday: Aclaris Therapeutics Inc (ACRS), Agilent …” and published on November 16, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>